Login to Your Account



FDA, Repros meeting: no new safety trials due for Androxal

By Randy Osborne
Staff Writer

Friday, February 7, 2014
The “not-testosterone” mantra long chanted by Repros Therapeutics Inc. with regard to its Androxal (enclomiphene), for secondary hypogonadism finally took hold, and the FDA agreed that the company will not need new safety tests before submitting the new drug application (NDA) before the end of this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription